Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
To enhance the utilization of biomaterials and nanomaterials by essential updates and upgrades
- Biomaterials 2019

Welcome Message

Dear Friends/Colleagues,

Greetings!

The 2nd International Conference on Biomaterials and Nanomaterials will be held from May 20th and 21st, 2019 in Vienna.

The mission of the Biomaterials 2019 has been to serve as a highly interactive community committed to promoting excellence in all aspects of biomaterial science and nanomaterial science with their relative science to improve human health and lifestyle.

In this sense, the Biomaterials 2019 Conference has been a major event for the biomaterial science and nanomaterial science with their relative science.

Biomaterials 2019 is a promising fascinating event, dedicated this year to “To enhance the utilization of biomaterials and nanomaterials by essential updates and upgrades”. This meeting provides an opportunity for academia, clinicians and industries to gather and discuss the latest trends and scientific breakthroughs pertinent to the field of biomaterial and nanomaterial from the bench to bedside.

In this conference, our main objectives are to encourage, foster and promote excellence in cooperative research and education in the biomaterial and nanomaterial science.

This is accomplished through:
  • A program of attractive showcasing international top researchers from various areas of biomaterial and nanomaterial along with their relative science.
  • The recognition of outstanding members with prestigious awards given at the conference.
  • Industrial promotions
  • Numerous B2B networking and collaboration opportunities
  • CPD credits
Another way in which Biomaterials 2019 supports its mission, is the promotion of the educational program. By organizing a variety of events, workshops, and exhibition during the conference, offering multiple opportunities for participants to receive mentoring and advice and gather scientific contacts, we aim to increase the active participation of younger members of this global population and bestow several awards upon young researchers and students.

Regards,

Organizing Committee
Biomaterials 2019


Sessions/Tracks


In recognition of the fact that speakers from industry need to protect their intellectual property, it is understood that some technical details cannot be disclosed. Biomaterials 2019 is once again soliciting abstracts for “Biomaterials Technology in Industry” sessions that will relax some of the typically rigorous scientific requirements for these specific sessions.  In recognition that speakers from industry need to protect their intellectual property, it is understood that some technical details cannot be disclosed. “Biomaterials Technology in Industry” abstracts should:

  1. Comply with the financial interest disclosures required of all authors
  2. Follow the standard abstract submission template, with allowable relaxation of the typically rigorous "methods" section, as appropriate to ensure that proprietary information is not compromised 
  3. Summarize the information the author intends to convey during the session
  4. Maybe purposely vague in areas that concern proprietary information
  5. Not be commercially driven, and should not promote specific products, or make product claims
NOTE: These sessions will be specifically delineated as distinct from the Scientific Program of the Annual Meeting with the loosened requirements articulated ubiquitously.

Biomaterials have the potential to revolutionize the treatment of a myriad of medical conditions; however, bench to bedside translation is rare. This session will focus on success stories from industry (large company and start-up), academia, and academic-industrial collaborations, etc. in which biomaterials have either been translated to commercial use or are significantly far along in this process. Topics covered will include biomaterials-based device and drug delivery technologies that have gone from bench top development and preclinical evaluation to evaluation in clinical trials. The journey from idea conception through the development process will be discussed, using specific examples with supporting data. Presenters will be encouraged to elaborate on topics including lessons learned for their journey and advice on forming successful collaborations enabling translation.


The adoption of 3D printing, bioprinting, and other advanced techniques are increasingly used in new product development. In addition to advantages they may offer, these technologies have their own specific properties and limitations. While many of these processes use the same synthetic and biologic materials already used in a variety of marketed products, process-based risks must be reasonably determined and reduced to a safe level. There are notable examples of 3D printed products both in the United States and in other countries, with early adoption mainly in the creation of surgical guides and models. Other products include custom tracheal implants, pharmaceutical tablets, PEEK craniofacial plates, orthopedic implants, and the like. The ultimate promise for many is the potential to build engineered tissue structures, up to full organ replacements, to advance biomedical products well beyond the current limits. This session comprises a two-part panel discussion focused on various translational considerations, including (1) advancing technology out of the lab, and (2) translating technologies into products for broad clinical use
 

Students and postdocs: Medical technology requires more than just laboratory results to become a reality. Do you believe that your biomaterials-based research innovation has the potential to succeed in the medical device industry? Put your skills to the test in this unique session designed to challenge you to consider the commercialization aspects of your research. Individuals and groups (your choice) will be judged by experts from investing, industry, regulatory, and academia on the strength of their commercialization plans. Prizes will be awarded to the top teams, including the audience’s choice. To participate, submit an abstract that contains your Executive Summary, including information on your technology, the market, and the commercialization strategy. Those selected will give a 10-minute pitch followed by Q&A “Shark Tank” style from judges and audience. For download complete instructions click here.
 


3D bioprinting is a fabrication technique used to mimic the anatomical complexity of native tissue, via a bottom-up approach, by depositing polymeric or cell-laden hydrogel-based inks, in a layer-by-layer fashion. 3D bioprinting is a promising approach and to some of the most daunting obstacles facing the field of tissue engineering and regenerative medicine, including vascularization of tissue constructs, the creation of complex architectures, and directing stem cell differentiation. The proposed session focuses on the recent advancements in 3D bioprinting technology in the development of complex, anatomical structures, motivating its use in a variety of biomedical applications such as regenerative medicine, tissue modeling, pharmacological assessment of therapeutics and modeling disease pathophysiology. Contributions regarding the use of different bioprinting modality, along with recent development in advanced bio-inks, are of interest to this session.


An understanding of the cellular and molecular mechanisms of human disease leading to the development of innovative therapies is a primary research goal. A barrier to understanding the disease microenvironment is the lack of a realistic tissue model for the long-term study of disease mechanisms. Two-dimensional culture systems are a widely used model for the studies on disease progression and preclinical drug assessments., however, they fail to reproduce the in-vivo disease microenvironment and the data produced are not always predictive. Advances in 3D printing may offer the potential to create in vitro tissue models that mimic the in vivo disease microenvironment. Such disease models can be used to investigate mechanisms of disease progression, for drug development and toxicology testing, and can eliminate the need for animal experimentation. The focus of this symposium will be on 3D printing technologies and the opportunities and challenges leading to the development of disease models.


3D bioprinting has great potential to be a powerful tool for fabricating complex 3D tissues. However, there are still significant challenges in this field. The current choice of printable materials is very limited. There is great need to develop better bio printable materials that exhibit good printability and proper mechanical properties. This proposed session will select abstracts reflecting the most recent advances on printable biomaterial development, advanced printing technology, and promising biomedical applications.

Session on: Cardiovascular
 

To develop new treatment strategies for cardiovascular diseases, some of the challenges include vascularization of synthetic tissues, renewable cell sources, biomaterials that have similar features to the native cardiovascular tissues, and efficacy in preclinical models. In this session, we will cover topics ranging from emerging biomaterials, injectable hydrogels, strategies of vascularization of engineered constructs, and advances in cardiovascular tissue engineering that have shown progress into clinical translation. Topics of interest include vascular grafts, valves, cardiac patches, and stem cell therapeutics.


Biodegradable vascular scaffolds: new designs, new evaluation methods and insights Biodegradable vascular scaffolds (BVS) were conceived as circumventing the biocompatibility concerns associated with durable foreign body implants while providing mechanical support and drug elution profiles similar to metallic stents during the early recoil prone phase. Yet after years of development and eventual FDA approval of the first BVS, the company decided to pull it from the market in light of clinical data showing higher levels of thrombosis in small arteries. This session will include a lead speaker (physician-scientist) who will shed new light on the interpretation of recent clinical data, and provide a forum for abstract submissions on emerging coronary BVS designs, and showcasing new methodologies for their design and evaluation, including computational modeling.


Thrombosis is often a major concern with cardiovascular medical devices such as stents, vascular grafts, heart valves, pacemakers, defibrillators, ventricular assist devices, cardiopulmonary bypass, and an artificial heart. Although significant progress has been made in developing and using a wide variety of metallic, polymeric, ceramic, and natural biomaterials for making cardiovascular medical devices, still the blood compatibility of these devices remains an issue. This general session will focus on (i) recent developments in cardiovascular biomaterials for improving blood compatibility; (ii) the development of novel biomaterials for applications in cardiovascular medical devices; (iii) novel coatings and surface modification technologies for improving blood compatibility; (iv) in vitro and in vivo evaluation of blood compatibility of biomaterials; (v) clinical evaluation of cardiovascular medical devices; (vi) novel approaches to improve endothelialisation of cardiovascular implants and devices; (vii) interactions of vascular cells with biomaterials.

 

Biomaterials have been invaluable tools for understanding how cells respond to their microenvironment in both health and disease. Here, we invite contributions that develop biomaterial platforms for cell culture or tissue engineering. Session topics include the following: understanding of the mechanisms that determine cellular and immune responses to disease/injury/biomaterials determining how biophysical and biochemical cues alter cellular behaviour in 3D, identifying differences between 2D and 3D microenvironments in mediating cellular phenotype or response to treatment, developing complex tissue microstructures/organoids, culturing multiple types of cells within complex microenvironments, driving or enriching specific populations, developing improved approaches for utilization of patient-derived or difficult to culture cells, drug screening within engineered microenvironments, and engineering microenvironments for therapeutic purposes.


Automated high-throughput platforms are powerful tools to study combinatorial effects of biomaterials on cellular response. These strategies present unique advantages over traditional methods for investigation of cell-material interactions. High-throughput platforms have the ability to screen a large number of samples in parallel while using a minimum amount of samples and provide rapid and precise analysis. This session will discuss biological applications of high-throughput systems to modulate cell microenvironments by optimizing suitable material combinations. In addition, the use of high-throughput set-ups for studying various cellular behaviors such as adhesion, growth, proliferation, and differentiation for tissue engineering applications will be covered. In addition to microarray platforms, microfluidic high-throughput systems for controlling cell behavior will also be highlighted by this session.


This session solicits abstracts that focus on the development of functional biomaterials for tissue engineering applications. Specifically, studies that investigate biomaterial-directed cellular response in the absence of external factors (e.g., growth factors) will be highlighted. These studies include the development of novel biomimetic approaches for the generation of tissue scaffolds with physicochemical properties (e.g., topography, composition, structure, mechanics) akin to the target tissue and assessment of the impact of these physicochemical cues on cell migration, proliferation, differentiation and DiNovo matrix production. Further, this session will also showcase in vivo studies that demonstrate the clinical translational capability of next-generation functional biomaterials. Lastly, studies that focus on the investigation of biomaterial-based mechanisms that modulate cellular response are of interest.
 
 

This symposium will focus on the development of products that are a combination of both a device and a drug. These types of innovations are anticipated to have an expanding role in healthcare. Disease areas where device-drug combinations are becoming increasingly important include cardiology, infection, diabetes, neurology, and oncology, to name a few. This session aims to provide a broad overview of the field and welcome speakers to provide insight into cutting-edge new technology and research.


Hearing loss presents a growing public health problem, with 15% of the global population affected across all age groups, leading to direct and indirect costs of untreated hearing loss totaling $750 billion. The incentives for developing drug or cell-based therapy to address this problem are huge, yet still unmet due to complex physiological barriers. However, as will be reviewed by the two invited speakers in this session, advances in this area including regenerative medicine coupled with novel drug delivery approaches give hope for the emergence of truly protective and restorative therapies soon. The first invited speaker is a clinician and the second a biomedical engineer. Solicited abstracts will provide industrial and academic researchers a forum for presenting emerging technologies in the field.
 


Guided bone/guided tissue regeneration, GBR/GTR, strategies are widely used in dental/craniofacial repair/reconstruction to enhance bone healing/formation for implant therapies. GBR/GTR membranes work primarily by acting as a barrier to prevent invasion of soft tissue into regenerating bone grafted sites. While current membranes act primarily in a passive manner, new and developing membranes are providing adjunctive bioactive activities to stimulate healing, bone formation and or infection. Because of the success of GBR/GTR membranes in dental/craniofacial applications, they are being explored for use in large orthopedic defects, neuro-regeneration, and in other soft tissue repair strategies. This session will provide an overview of the clinical use and performance of GBR/GTR membranes in dental/craniofacial repair as well as focus on advances in GBR/GTR membrane strategies in tissue healing and regeneration.


Progress in material science, sensors, and fabrications technologies have enabled the development of sophisticated, Smart ‘sense and respond’ dental materials for clinical dental applications. Additional functionalities of this new generation of smart dental materials have focused on both clinical and biological functions. The former includes improved aesthetics, material strength, and adhesion. Besides superior biocompatibility, biomaterial properties that promote therapeutic responses include antimicrobial activity and improved pulp-dentin healing, among others. This session will focus on novel biomaterials to improve patient care for oral, dental, and craniofacial applications.
 
Session on: Diabetes/Dialysis
 

Type 1 diabetes is an autoimmune disease in which the insulin-producing beta cells of the pancreas are destroyed. This symposium will focus on translational biomaterials technologies for type 1 diabetes to improve survival, function, and/or delivery of insulin-producing cells or to improve diabetes monitoring and standards of care. Examples include (i) materials delivering bioactive or immunomodulatory therapies, (ii) biomaterials addressing islet hypoxia, inflammation, and vascularization, (iii) biomaterial strategies for delivery of renewable sources of beta cells, and (iv) advancements in implantable glucose sensing technologies.


2.5 million people worldwide are on dialysis. Cost is high as are complications and morbidity. Most all dialysis technology involves biomaterials. This session will examine new biomaterials technologies that can improve outcomes and reduce costs. Blood compatibility, membrane technologies, blood access, skin healing, sorbents, and non-fouling technologies are of special interest for next-generation dialysis.
 
Session on: Drug Delivery
 

Controlled release approaches have the potential to effectively treat a variety of medical conditions while avoiding complications such as off-site toxicity and drug-resistance. Approaches can include localized, depot-based methods as well as targeted, systemic treatments. Controlled drug delivery can result from affinity interactions, bond cleavage, reservoir or diffusion-based control, and/or stimulus-responsive methodologies. This session will focus on the development of these drug delivery systems, which include nano and microparticles, hydrogels, scaffolds, and thin films, for applications including but not limited to regenerative medicine/tissue engineering, cancer, microbial infection, and autoimmune diseases.


This general session will focus on recent advances in delivering drugs, proteins, growth factors, and a gene from implant surfaces and coatings. These local delivery systems have tremendous applications in orthopedic implants, fracture fixation devices, dental implants, cardiovascular devices, craniofacial implants, ophthalmic implants, cochlear implants, and neural devices. This session will cover a wide range of delivery platforms that are currently available for different implant surfaces. These include novel biodegradable, biostable, and biological polymer coatings, ceramic coatings, porous, textured, micro-rough, and reservoir surfaces, organic and molecular coatings, self-assembled coatings, sol-gel coatings, biodegradable metal coatings, thin films, biological, biomimetic and mineral coatings. This session will also highlight the importance of different surface characterization techniques to study such coatings. A special emphasis will be provided to the implant coating technologies that have been translated into preclinical and clinical products.


Targeted genome editing using programmable nucleases has recently rapidly transformed from a technique on the bench to a potential avenue for the treatment of genetic disorders and diseases. Three main types of nucleases, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered, regularly interspaced, short palindromic repeat (CRISPR)-associated endonuclease Cas9 have been harnessed to introduce precise and specific genome sequence change at virtually any genome locus of interest. The therapeutic relevance of genome editing, however, is challenged by the safe and efficient delivery of nuclease into targeted cells ex vivo and in vivo. This symposium will cover the fundamentals, perspective, and a challenge of genome editing, and highlight the recent advances that have been made on non-viral delivery of genome-editing nucleases for therapy.


Nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S) and other small gaseous molecules are now co-classified as endogenous gasotransmitters with profound effects on mammalian physiology and major implications in therapeutic applications. Although gasotransmitters have wide-ranging therapeutic potential, their clinical use is limited by their gaseous nature, systemic toxicity, off-target effects, short half-life, and extensive reactivity. While there are many small molecules that can slowly release gasotransmitters under physiological conditions, most are quickly cleared in vivo and cannot target specific sites. Therefore, biomaterials that can controllably deliver gasotransmitters being developed. This session will explore the delivery and therapeutic potential of small gaseous signaling molecules from biomaterials.


Targeted and stimuli-responsive biomaterials, or “smart” drug delivery systems, can be used to effectively treat a variety of medical conditions. These materials have the potential to act rapidly and effectively, while avoiding various complications (e.g., off-site toxicity). Common stimuli used to trigger a change in these materials include pH, temperature, ionic strength, chemical and/or mechanical microenvironment, redox potential, and light. This session will focus on the development and application of these targeted and/or stimuli-responsive biomaterials including, but not limited to, cancer therapy and diagnostics, infection, cardiovascular disease, autoimmune diseases, etc.

Session on: Education
 

Biomaterials Education Challenge (E&PD). As in previous years, the biomaterials education challenge will encourage SFB student chapters and other student clubs or groups to develop innovative and practical approaches to biomaterials education. Student teams will be tasked with developing an educational module for middle school science classes that highlight the fundamentals aspects of biomaterial system.
 
 

Carbohydrates, including monosaccharides, oligosaccharides, polysaccharides, and their conjugates, are key structural and signaling elements in living systems. Understanding the roles of carbohydrates in nature has led to increasing opportunities to leverage them as both therapeutic targets and active components for biomedical and biotechnological applications. Carbohydrate-containing biomaterials (i.e. "glycomaterials") are particularly attractive because they provide unique opportunities to mimic the multivalent carbohydrate presentation in native glycoconjugates that is often central to carbohydrate function within living systems. This session will highlight recent advances in the synthesis, characterization, and use of glycomaterials to interrogate and harness the biological activity of carbohydrates. Particular emphasis will be placed on synthetic glycomaterials to probe glycocalyx function, modulate protein activity, and engage the immune system for infection prophylaxis and immunotherapy.


There are increasing demands for biomaterials that are responsive to local stimuli (e.g. change in pH, ionic strength, light, temperature), and/or play multiple biological roles in a single application (e.g. tissue engineering, drug delivery, and treatment of cancer, tumor, cardiovascular disease, infection). Various approaches have been studied to develop multifunctional biomaterials including 3D printing, electrospinning, self-assembly, photolithography, and so on. In this symposium, the recent developments and breakthroughs of biomaterials with multiple biological functions and the methods to create such biomaterials will be reported along with the challenges and translational studies. Mixed presentations from the U.S., Canada, Europe, and other countries are expected.


Metallic biomaterials have been widely used in many medical implants. Traditional metallic biomaterials such as Titanium, Stainless Steel, and CoCr have been used in various implantable devices. Recently, more innovative metallic materials have been developed, which include smart materials and biodegradable metals. Topics will include research on various metallic biomaterials, designing/manufacturing metallic medical implants, and study on biological behaviors. Novel fabrication technologies or applications for metallic biomaterials will include materials for use in cardiovascular, neurovascular, and dental applications, as well as various prosthesis, among others.


Click chemistry has emerged as a powerful tool for biomaterial synthesis. A key advantage of chemical reactions fitting the click chemistry paradigm is that they are highly selective and, thus, provide greater control over material structure and properties. Click reactions are also fast, efficient, proceed under mild conditions, and produce only inoffensive byproducts. Because of these advantages, click reactions are now being leveraged to synthesize and functionalize novel drug delivery systems, tissue engineering scaffolds, and biosensors. They are also being used to create dynamic materials to probe cell behavior within engineered microenvironments. This session aims to highlight the role of click chemistry in developing novel biomaterials for these and other applications. Submissions describing efforts to expand the click chemistry toolkit in biomaterials and to elucidate the intricacies, unique advantages, and challenges of specific click reactions are also of interest.


Precisely designed biomaterials are a powerful tool for reproducing and studying the complex structure, mechanics, and composition of pulmonary tissues. Here, we invite contributions that design, develop and implement biomaterial solutions for the diagnosis and treatment of acute and chronic pulmonary diseases and complications. Specific areas of interest are regenerative medicine, controlled therapeutic delivery, use of biomaterials for acute pulmonary complications, development of biomaterials for thoracic surgery and personalized disease modeling.


This session is dealing with various subjects related to the fabrication, characterization, and clinical translation of novel biomaterials substituting epithelium, such as skin, cornea, bronchi, and other epithelial tissues. The uniqueness of these epithelia is multilayered structures allowing different cell types are functioning, which have been extensively studied in fabricating artificial, cornea, alveolar epithelium, and ----, for drug screening and cosmetic science as well as complete tissue regeneration of the related tissues. The industry, as well as academia-based researches, are welcomed submit abstracts related to studies on any epithelium or parts of the epithelium.


Bioelectronics, electronics designed to interface with biology in vitro and in vivo, are an important class of biomaterials that are gaining significant interest. Bioelectronic devices include: (i) wearable sensors for health monitoring, (ii) in vitro diagnostics and biosensors that provide an electrical signal output proportional to an analyte, (iii) implantable devices (e.g. pacemakers, blood glucose monitoring, drug delivery, optoelectronics), (iv) electrophysiology (ECG, EMG, EEG) and (v) electrical stimulation of cells or tissues for tissue engineering, enhanced regeneration and therapeutic intervention. This symposium will highlight recent efforts in bioelectronics, including fabrication advances for improved properties such as size, softness, flexibility, degradability, and biocompatibility as well as investigating their use in new applications.


The past decade has seen a revolution in grassroots innovation and creativity due to the development of open-source and/or low-cost fabrication tools and software. This is leading to major advances in biomaterials fabrication in terms of new materials and design strategies and redefining the manufacturing process. The open-source licensing is important because it enables widespread access to these technologies with the ability to modify the software/hardware and then contribute improvements back to the community. Further, the low cost of many of these technologies enables a wider range of scientists and engineers to leverage these capabilities in their own labs, even in resource-limited and educational environments. The scope of this session spans from 3D printing to laser-based cutting and polymerization, to microscope design/automation to image analysis, and to other open-source technologies being developed and used by the biomaterials research community.
 
Session on: Immune


Therapeutic modulation of the immune system is the emerging paradigm in medicine. For example, immunotherapy holds the promise of a cure for cancer and is poised to expand into other therapeutic areas, such as inflammatory disorders, autoimmune diseases etc. However, several frontiers in immunotherapy remain to be explored. For example, can we design biomaterials for precise modulation/education of the immune system while avoiding toxicities? How can we locally active the immune response? Can we track the immune cells in real-time? The session will focus on engineered biomaterials for therapeutic immune modulation. Specifically, the session will cover topics ranging from biomaterials for delivery of immunomodulators and imaging agents, scaffolds, cell-based therapies etc. Several cutting-edge immune engineering platforms will be included.


This session will focus on clinically and immunologically informed devices that leverage material-tissue interactions to harness the immune system for instruction, reprogramming, and/or diagnosis of disease. Potential submissions could range from implantable devices for diagnostics or too smart materials that modulate the immune system in the context of disease. There is not a specific disease focus for the session, yet abstracts should succinctly indicate the clinical and commercial background for their disease area. Priority will be given to submissions where utilization of the biology of disease (e.g., molecular pathways) is the premise of their research. For example, how are the aberrant inflammatory pathways in cancer or autoimmunity factored into the material, device, or experimental designs? Submissions should also indicate if the approach is primarily a tool for deciphering disease biology or if a feasible path to clinical translation exists. Moreover, submissions should address what challenges and opportunities exist within the area of focus.


Micro- and nanoscale devices have become increasingly used in medicine as platforms for delivering peptides, proteins, and cells. These devices are often capable of targeting specific tissues or achieving release kinetics that enhances their efficacy or mitigates off-target toxicity. Achieving the desired interaction with the host immune system—whether that involves evading or promoting a particular response—is central to the function of most of these devices. This session will explore emerging applications of micro- and nanotechnology for immune modulation such as cancer vaccines, protein delivery, and cell therapy. Advances in micro- and nanoscale manufacturing techniques (e.g. self-assembly, microfabrication, 3D printing), the development of novel materials, and innovative device designs are of particular interest.


Use of biomaterials in engineering the immune system is growing. In fact, development of new biomaterials and utilization of existing biomaterials for actively modulating the immune system is at the forefront of biomaterials innovation. Modulation of the immune cells is being sought to treat disorders related to the immune system including autoimmune disorders, cancer, and infectious diseases. This symposium will focus on strategies that are trying to bring biomaterials-based systems to the market including drug delivery approaches, load-bearing implants, biomaterial-tissue interfaces, and biomimetic devices.
 
Session on: Nano


The scope of this symposium is on biomedical nanomaterials, discovery,  synthesis, characterization, and devices with the focus on drug delivery,  biomineralization, implantable device development/characterization, and the host response to such implantable devices. Next generation medical nanodevices and nano-biomaterials are expected to revolutionize the future of medicine. This symposium provides an opportunity for the medical and scientific communities to be exposed to recent advances in nanomedicine, new materials, and implant technologies. Researchers and engineers will be able to learn about the clinical and patient needs from the medical community perspectives and clinicians will become aware of the recent technological advances that can promote better medical practices.


Due to their versatility and diversity in materials properties, a wide range of biomedical applications have emerged in recent years employing supramolecular nanomaterials. By leveraging specific, tunable, and non-covalent interactions, the rational design of functional objects at the nanoscale has been used to develop individual nanoparticles or to produce highly oriented materials for a growing number of applications including drug delivery, imaging, theranostics, and vaccines.


Efficient delivery of therapeutics (including small molecule drugs or large proteins) is important to stimulate the repair or regeneration of damaged or diseased tissues. Synthetic nanoengineered materials can be tailored for therapeutic delivery to cells and tissues for a range of biomedical applications. By modulating the physiochemical characteristics of nanomaterials we can customize therapeutic efficacy, cellular internalization, biodistribution, and in vivo retention. This session will focus on emerging approaches in designing advanced nanomaterials for therapeutic delivery. Of special interest in this session are: delivery of small molecule drugs and large therapeutic proteins for regenerative medicine, stem cell engineering, immune modulation, antimicrobial, cardiovascular diseases, and cancer therapeutics.


Advances in nanoparticle imaging probes are transforming imaging capabilities in preclinical research and clinical diagnosis. This symposium will focus on the underlying science via understanding structure-function relationships, applied engineering via the design of functional imaging probes, and translation from the laboratory to the clinic. Relevant imaging modalities include anatomic, functional, and molecular imaging using CT/X-ray, MRI, nuclear, optical, and ultrasound. Particularly timely topics include immuno-targeting, overcoming the tradeoff between circulation and clearance, stimuli-responsive probes, theranostic probes, and imaging for precision medicine.

Session on: Neural


Researchers are constantly developing and applying new biomaterials to the challenging problems of the peripheral and central nervous systems. Engineered biomaterials are uniquely positioned for use in creating, testing, and regenerating neural tissue for better in vitro models of injury and disease, therapeutic treatments, understanding neural development, and mapping the brain. This session will focus on cutting-edge research in neural biomaterials including fundamental material development through pre-clinical studies. These include big questions surrounding diseases and injuries spanning neurons, astrocytes, oligodendrocytes, microglia, and Schwann cells. Presentations will be highly interdisciplinary at the interfaces of biology, chemistry, materials science, engineering, and neuroscience. Target applications of these materials include neural injury, neurodegenerative diseases, stroke, diagnostics, brain-machine interfaces, and brain cancer.
 
Session on: Orthopedics


Natural and synthetic biomaterials have many advantages for bone regenerative applications, particularly in avoiding the morbidity associated with autograft procedures. Next-generation phosphates, such as Brushite and Monetite as well as Mg- and Sr-phosphates provide enhanced biomaterial properties for orthopedic applications. This symposium will provide an overview of magnesium phosphate in bone graft substitute and coating applications and invite abstracts from researchers studying ceramics for bone applications. Topics are anticipated to include bioactivity, drug delivery, resorption, and cell loading.


Microbial infections are among the leading causes of death worldwide. Drug resistance and lack of new antimicrobial therapeutics increase the difficulty of treating these infections. Microbial biofilms can also severely complicate treatment and lead to chronic infections. These three-dimensional, surface-attached microbial structures can form on a range of medical devices and biological surfaces and exhibit sophisticated defense mechanisms, evading traditional antimicrobial therapies. This session will focus on recent advances spanning industry and academia in developing materials for the treatment of bacterial, fungal, viral, biofilm and polymicrobial infections. Strategies discussed may range from a synthesis of new antimicrobial molecules and macromolecules to fabrication of antimicrobial surfaces, device coatings, nano- and micro-particle drug carriers, hydrogels, etc.
 


The Biomaterials Education SIG is soliciting abstracts pertaining to education and professional development.  From teaching and learning to new approaches to knowledge transfer and implementation of innovative ideas. Studies around bridging the gap between classroom theory and clinical application and hastening translation are also welcome.


The Biomaterials and Medical Products Commercialization SIG session seek abstracts on the topics of translational research, pivotal animal studies, clinical trials, manufacturing and automation, alternatives to traditional testing (e.g. simulation), regulatory science, technology transfer, and entrepreneurship, as well as other subjects related to biomaterials and medical device commercialization efforts.


The Biomaterial-Tissue Interaction SIG session will consider abstracts that investigate, in vitro and in vivo, the effects of biomaterial properties, characteristics or modifications on a molecular, cellular, and physiological process. These events initiate with specific interactions between biomaterials and biological molecules present in tissues after biomaterial implantation, followed by cell recognition and activation of cellular processes such as cell attachment, proliferation, activation, polarization, differentiation, and necrosis. Understanding these events is the purpose of the Biomaterial-Tissue Interaction (BTI) Special Interest Group.


Cardiovascular therapies harness biomaterials for optimizing biocompatibility, releasing drugs and as scaffolds for tissue regeneration. The session will provide a forum for research on the development and assessment of cardiovascular biomaterial applications across this entire spectrum.


The Dental/Craniofacial Materials SIG session focuses on the basic, applied, and clinical research of innovative biomaterials ranging from synthetic to biological origins. These bio-inspired materials are designed to repair dental/craniofacial tissue structures, restore their functions, and/or regenerate these tissues using tissue engineering approaches. Recent advances in dental biomaterial technologies include advanced bio-inspired inorganic, organic, and composite nanomaterials, controlled drug delivery strategies, surface modification, and 3D printing technology.


The Drug Delivery SIG session will consider abstracts that fall with the broad areas of therapeutic development, formulation, and application testing. Drug delivery from medical devices, tissue engineering scaffolds/hydrogels, films, microparticles, nanoparticles, environmentally responsive materials, and other types of biomaterial assemblies are all invited.  Studies testing drug targeting, drug combinations, and drug/cell combinations are all also welcomed to submit. Drug delivery application areas of interest include but are not limited to regenerative medicine/tissue engineering, cell and tissue transplant, cardiovascular stents and other devices, cancer, microbial infection, and autoimmune diseases.

 
The Engineering Cells & Their Microenvironments Special Interest Group focuses on approaches to alter cell microenvironments. These approaches can be used to control biomaterial-induced cell signaling to enable stem cell manufacturing and differentiation, immuno-engineering, as well as for the development of biomaterials for cell-based detection and diagnosis. These biomaterial-based approaches can also be utilized to direct cellular responses (e.g., proliferation, differentiation, morphological regulation, motility, matrix production) without the addition of external growth factors, chemicals, or drugs, thereby mitigating potential side-effects and facilitating improved in vitro and in vivo cellular outcomes. This session will focus on translation of these techniques toward a variety of specific applications ranging from, but not limited to, tissue engineering for dynamic disease models and regenerative medicine to therapeutics and direction of stem cell differentiation. Studies that develop biomimetic materials which provide specific physicochemical cues (e.g., composition, topography, stiffness) to achieve a desired cellular response will also be highlighted.


The  Immune Engineering SIG is soliciting abstracts that deal with engineered biomaterials for the development of immunotherapeutics and immune microenvironment engineering, to uncover fundamental mechanisms of immunobiology, and for systems immunology.


The nanoscience and nanotechnology of biomaterials involve the unique science and technology present in biomaterials at the nanoscale and their related biological effects. Such nanomaterials present the creation of new and better biomaterials and devices, diagnostics, and therapeutics for biomedical applications.


The Ophthalmic Biomaterials SIG Session welcomes submissions that describe the development and/or testing of biomaterials for use in ophthalmology. This may include drug delivery strategies or cell-based approaches, regenerative medicine applications, or unique animal models that have a primary focus in preserving or restoring the form and/or function of the eye. Abstracts from related areas of research with strong applicability in the visual system may also be submitted for this SIG Session. 


Orthopedic biomaterials may include all kinds of biomaterials for orthopedic applications (e.g., bone implant/scaffold, 3D printing, drug delivery) and related biological effects. Such biomaterials may include metals, ceramics, polymers, composites, coatings, biodegradables, etc.


The goal of this broad session is to advance the understanding of cell and protein interactions with natural and synthetic biomaterials. Recent advances related to the mechanistic interactions with existing biomaterials and the design of new materials to produce targeted responses by proteins and cells are encouraged. Topics of interest include, but are not limited to 1) relating surface chemistry to protein adsorption or specific binding; 2) studying the activation or inactivation of protein function at interfaces, including complement activation; 3) the response of cells to materials with varied chemistries, mechanical properties, and micro- or nanostructured surfaces; 4) the evaluation of cell and tissue responses to biomaterials with respect to changes in function or fate; and 5) the role of surface receptors in cell responses, including mammalian and microbial cell types.


Some research areas that fall under these topics include polymer coatings, grafting, plasma polymerization/treatment, self-assembled coatings, thin film deposition, surface modifications such chemical and ion surface modifications; spectroscopic, microscopic, and biochemical surface characterization; device-tissue interactions, non-fouling surfaces, antimicrobial coatings, and other implantable medical devices.



Session on: Surfaces


Surface modification has become a routine procedure in designing and developing bio-friendly implants for orthopedic, dental and pacemaker applications as well as other biosensing applications. The surface of a biomaterial affects its performance in a host environment. Many techniques have been utilized to modify the surfaces of biomaterials to obtain innovative or improved properties (e.g. mechanical, biocompatible, corrosion-resistant, and biological responsive) through modification of physicochemical interactions between the biomaterial and the biological environment at the molecular, cellular, and tissue levels. In this session, recent advances in surface modification technologies and characterization, biomaterial-tissue interactions at the interface, and basic and translational studies of surface modified biomaterials will be solicited and presented.


Biomaterials can be designed to radically enhance the efficacy of the next generation of biologic and biosimilar therapies. This topic will cover the most advanced strategies of combining biomaterials with biologic drugs to radically enhance its therapeutic efficacy and avoid its side effects.

Session on: Tissue Engineering


This session focuses on various approaches to fabricate cell-dense constructs including micro- and nano-engineered biomaterials platforms, bioprinting techniques, cell sheet engineering and aggregation of modular micro-tissues. For many applications, the use of synthetic scaffolds to guide tissue architecture is not suitable because they reduce cell density and limit cell-cell interactions; instead, cell-based bottom-up approaches enable greater cell fractions and rely on the principles of self-assembly to control and direct the formation and organization of tissue modules. Both scaffold-free approaches and organoid based models are welcome. This session will provide a forum for scientists, engineers, and clinicians to discuss recent technological advances that enable quantitative and predictive in-vitro and in vivo models for tissue engineering, and drug testing. Development of both health and disease-specific models are also of interest.


The session will focus on cutting-edge approaches that integrate biomaterials and bio-fabrication to engineer functional tissues. A diverse range of novel technologies has been recently leveraged to manufacture biological structures with precise control over multiple length scales, including 3D printing, electrospinning, microfluidics, light-based patterning, and directed assembly. The session will highlight the methods that have enabled major advances in organ integration, production of tissue models, single cell-level presentation of microenvironmental cues, and molecular-level control of biomaterial composition. Considering the interdisciplinary nature of this research, the session broadly invites presentations from both academia and industry with emphasis on collaborative research efforts to combine fabrication techniques and to develop high-throughput, scalable processes in bio-fabrication.


Musculoskeletal tissue interfaces (e.g., tendon-to-bone; ligament-to-bone, cartilage-bone) present unique challenges to the field of tissue engineering. A major challenge is a striking cellular, biomolecular, and structural heterogeneity of these tissues, which can be hierarchical, graded, and heterogeneous over multiple lengths and timescales. This session will highlight ground-breaking work in our field developing biomaterials that replicate or guide regenerative repair of such heterogeneous tissues. The session will also highlight analytical strategies to characterize structure-function-property relationships associated with these tissues and their biomaterial analogs.


Due to disease, degeneration, or trauma, there is a tremendous need to repair damaged tissues and organs. Although surgical replacement can be performed to address this issue, the insufficient number of donors greatly limits the applicability of this approach. Therefore, it is essential to develop engineered multifunctional biomaterials to promote tissue regeneration. Regenerative engineering combines biomaterial-based approaches with stem cell therapies and developmental biology to regenerate or repair tissues and organs. This session will cover tunable biocompatible materials such as hydrogels, fibers, proteins, carbohydrates, nano/micro-porous scaffolds, and metals, to modulate cellular microenvironments. The biomaterials that can direct cell fate and promote differentiation will also be highlighted by this session. Moreover, the biomaterials that can facilitate drug delivery and immunomodulation will be covered through oral and poster presentations. Furthermore, we will include discussions for the development and commercialization of various medical devices such as blood-contacting implants, prostheses, and pacemakers in the session. In addition to engineering approaches, we will also provide discussions on clinical translation of biomaterial-based strategies. We expect that our interdisciplinary session including material science, chemistry, biology, engineering, and medicine will be of great significance to the clinicians, industry members and professors in academia.


As a field, biomedical engineering continues to change the landscape of options available to individuals facing reproductive or endocrine failure for various reasons, such as genetic predisposition, age, iatrogenic effects of treatment, or disease. Engineered reproductive tissues that restore and support normal organ function are now emerging from work being done at the interface of reproductive biology, materials science, bioengineering, and advanced manufacturing. These engineered reproductive tissues and culture systems are enabling more physiologic in vitro modeling of homeostasis, development, disease, pregnancy, and aging. They are also being used for efficient screening of new pharmacologic agents for efficacy and reproductive toxicity. In this symposium, we will focus on recent work describing new engineering methods and applications in reproductive science and medicine, with a focus on biomaterials and microfluidic approaches that permit the generation of functional constructs at the “tissue/organ” level for use in both research and the clinic, with broader applications in other fields.


As the demand for precision medicine continues to rise, the “one size fits all” approach to the design of medical devices and therapies to treat specific diseases and injuries is becoming increasingly outdated. Biomaterials have significant potential for transforming precision medicine, and individual patient complexity often necessitates integrating multiple functions into a single device to successfully tailor personalized therapies. In this session, we seek to highlight the latest research in biomaterials-based technologies that enable precision medicine, such as implantable devices for the in situ, real-time analysis of a patient’s condition or customized devices or material chemistry that adapt to a specific patient’s biology. We aim for our session to demonstrate that biomaterials-based technologies may address limitations to current approaches in precision medicine and may allow for more personalized therapies for patients.

Session on: Wound Care


Stopping bleeding (hemostasis) and providing short and long-term wound care via passive and/or bioactive mechanisms is an important area of biomaterials-based technologies and includes external, intracavitary and intravascular hemostats, dressings, powders, foams, fibers, and gels. The goal of this session is to highlight recent advances in hemostatic biomaterials and to facilitate discussion of best practices for moving hemostatic technologies from the benchtop to the clinic. The proposed session will invite presentations from researchers in this field that discuss biomaterials design, structure-property-function relationships, and achieved/ongoing/future visions of technology translation pathways. An emphasis will be placed on translational aspects of hemostatic technologies.


There is an urgent need for tissue adhesives that can provide convenient and simple methods to seal wounds and affix medical devices on and in the body. While there are multiple types of adhesives under development, the need remains critical and there exists a wide gap between what academic labs are producing and what clinicians need. This session is intended to close the gap by engaging researchers in multiple sectors - including chemists and biomaterials experts, companies, and clinicians to present the latest innovations and challenges that remain.

Past Conference Reports

We would like to thank all our wonderful keynotes, speakers, conference attendees, students, associations, media partners, exhibitors and guests for making Biomaterials 2018 a successful and splendid event.

Allied Academies hosted the International Conference on Biomaterials and Nanomaterials during October 22-23, 2018 at Mercure Hotel Kaiserhof Frankfurt City Center, Frankfurt, Germany with the theme “Imparting the Incredulous Applications of Biomaterials in Research & Industries”. Benevolent response and active participation were received from the Editorial Board Members of supporting International Journals as well as from the leading academic scientists, researchers, research scholars, students and leaders from the fields of Materials science and Robotics who made this event successful.

The conference was marked by the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 28 countries, who have driven this event into the path of success. The conference highlighted through various sessions on current retroviral research.

Biomaterials witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the fields of Biomaterials, Materials Science, Nanomaterials, Biomedical Engineering, Mechanical Engineering.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures. The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honourable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

  • Roger | Bostleman | NIST| USA
  • Desineni Subbaram Naidu | University of Minnesota Duluth | USA
  • Zhenan Bao | Stanford University | USA
  • Jin-Woo Jung | Dongguk University | Republic of Korea
  • Jan Czernuszka | University of Oxford | United Kingdom
  • Polina Anikeeva | Massachusetts Institute of Technology | USA
  • Michiya Fujiki | Nara Medical University | Japan
  • Parmeggiani C | University of Florence and LENS | Italy
  • Raziel Riemer | Ben-Gurion University | Isreal
  • Daoxiong Gong | Beijing University of Technology | China
  • Jose Antonio Gomez-Tejedor | Universitat Politècnica de València | Spain
  • Xin Zhao | Nankai University | China
  • Dirk H Broer | Eindhoven University of Technology | The Netherlands
  • Baolin Huang | Guangzhou University | China
  • Gregory O’ Hare | University College Dublin | Ireland
  • Enrique Barrera | Rice University | USA
  • Junichi Takeno | Meiji University | Japan
  • Martin Heller | Johannes Gutenberg-University of Mainz | Germany
  • Cimpoesu N | Technical University Gheorghe Asachi of Isai | Romania

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Biomaterials 2018.

With the grand success of Biomaterials 2018, Allied Academies is proud to announce the 2nd International Conference on Biomaterials and Nanomaterials to be held during May 20-21, 2019 in Vienna, Austria. 

Renowned Speakers
OCM Member
Prof. Maria Cristina Tanzi
Scientific Director of Laboratory and Professor, Biocell Lab and Biomaterials Lab
Politecnico di Milano
Milan, Italy
OCM Member
Professor Shen-Ming Chen
Distinguished Professor, Department of Chemical Engineering and Biotechnology
National Taipei University of Technology
Tamsui District, Taiwan
OCM Member
Prof. Aharon Gedanken
Head - Kanbar Laboratory for Nanomaterials
Bar-Ilan University
Israel, Israel
OCM Member
Dr. Chandra P. Sharma
Founder of Society of Biomaterials & Artifical organs, India, Senior Scientist G and Head, Division of Biosurface Technology
Sree Chitra Tirunal Institute for Medical Sciences & Technology
Trivandrum, India
OCM Member
Thomas J Webster
Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering
Northeastern University
Boston, USA
OCM Member
Dr. Zhenan Bao
Professor of Chemical Engineering and Material Science and Engineering, Materials Science and Chemical Engineering
Stanford University
Santa clara, USA
OCM Member
Prof. Dr. Shiv Kumar Chakarvarti
Former Chairman & Dean Academics, NIT and Former Advisor Research, MRIIS
National Institute of Technology
chandigarh, India
OCM Member
Martin Pendola
Research Scientist, Orthopedics Department at NYU College of Dentistry
SUNY Downstate Medical Center
New York, USA
OCM Member
Sherif Elsharkawy
Research Scientist , The Centre for Oral, Clinical and Translational Sciences, Faculty of Dentistry, Oral & Craniofacial Sciences
Kings College London
London, United Kingdom

To Collaborate Scientific Professionals around the World

Conference Date May 20-21, 2019
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities
Venue
&
Hospitality

Join The Discussion

Allied Academies Global Conference Directory

Mail us at

Program Manager
biomaterials@materialsscienceconference.com
Sponsors | Exhibiting | Advertising
sponsoracc@alliedacademies.com
Event Co-ordinator | General Queries
biomaterialsconference@gmail.com
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions


Attendee Category:


Professionals: Lecturer, Professor, Researcher, Businessman

Young Research Forum: Post Doctoral Candidate

Students: School level, Under Graduate, Post Graduate, Ph.D

Delegate: Any professionals whoever wish to attend this Conference without any presentations



Responsibility:


Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.


Insurance:

Registration fees do not include insurance of any kind.


Transportation:

Please note that any (or) all transportation and parking is the responsibility of the registrant.


Press/Media:

Press permission must be obtained from Allied Academies Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied academies are a non-profit organization. This conference is not associated with any commercial meeting company.


Requesting an Invitation Letter:

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact biomaterials@alliedconference.net to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrant's account. Cancellation, Postponement, Transfer of Registration and all cancellations or modifications of registration must be made in writing to Program Manager (biomaterials@alliedconference.net or finance@alliedacademies.com)


Cancellation Policy:

If Allied academies cancel this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Conferences (AAC) event which must occur within one year from the date of cancellation.


Postponement:

If Allied academies postpone an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Conferences event which must occur within one year from the date of postponement.


Transfer of registration:

All fully paid registrations are transferable to other persons from the same organization if registered person is unable to attend the event. Transfers must be made by the registered person in writing to Program Manager. Details must be included with the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of the conferences. However, Registration cannot be transferred if it is intimated within 14 days of the respective conference. The transferred registrations will not be eligible for Refund.


Visa Information:

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible. Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only. Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.


Refund Policy:

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply, Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep refund policy is as following slabs-

Before 90 days of the conference: Eligible for Full Refund less $100 Service Fee
Within 90-60 days of Conference: Eligible for 50% of payment Refund
Within 60 days of Conference: Not eligible for Refund
E-Poster Payments will not be refunded.


Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to canceling or amending your booking, to ensure you are fully aware of any non-refundable deposits.


Highlights from last year's Convention

Copyright © 2019-2020 Allied Academies, All Rights Reserved.